NTRB NUTRIBAND INC.

Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

Nutriband Inc. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference

ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (Nasdaq: NTRB) (the “Company”) is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025.

The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company’s Chairman, Serguei Melnik in real time.

Mr. Melnik will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to or ask your questions during the event and Mr. Melnik will do his best to get through as many of them as possible.

Nutriband Inc. will be presenting at 09:40 AM Eastern time for 30 minutes.

Please register here to ensure you are able to attend the conference and receive any updates that are released.

 

If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, . We will release a link to that after the event.

About the Emerging Growth Conference

The Emerging Growth conference is an effective way for public companies to present and communicate their new products, services and other major announcements to the investment community from the convenience of their office, in a time efficient manner.

The Conference focus and coverage includes companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors, as well as Investment advisors and analysts.

All sessions will be conducted through video webcasts and will take place in the Eastern time zone.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.

Phone: 407-377-6695

Email:

SOURCE: Nutriband Inc.



EN
18/08/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NUTRIBAND INC.

 PRESS RELEASE

Nutriband Signs Exclusive Distribution Agreement with Innomedica for A...

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch....

 PRESS RELEASE

Nutriband Signs Exclusive Distribution Agreement with Innomedica for A...

Nutriband Signs Exclusive Distribution Agreement with Innomedica for AVERSA Fentanyl and all Sports Tape products for Costa Rica ORLANDO, Fla., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. today announced that it has signed an exclusive distribution agreement with Costa Rica Based Innomedica for AVERSA Fentanyl upon approval and all sports tape products manufactured at its Pocono Pharmaceutical / Active Intell subsidiary. Innomedica will also be overseeing and financing all regulatory approvals for the above mentioned products as they ramp up for launch. About AVERSA™ Abuse-Deterrent...

 PRESS RELEASE

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Disc...

Nutriband Inc. provides summary of Annual Shareholder Meeting Key Discussion Points ORLANDO, Fla., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) has provided an update to shareholders on the key milestones and discussions from this years Annual Shareholders Meeting, held on Jan 24, 2026 in Orlando, Florida. Details and highlights may be found below. Addition of Two New Directors Allesandro PudduAlessandro Puddu is an Italian Chartered Accountant and Statutory Auditor with over 10 years of experience in audit, corporate advisory and financial reporting f...

 PRESS RELEASE

Nutriband CEO Publishes Letter to Shareholders

Nutriband CEO Publishes Letter to Shareholders ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below. Dear Shareholders, As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our app...

 PRESS RELEASE

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Po...

Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), tod...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch